Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 8thAnnual Evercore Healthcare Conference on Thursday, December 4, 2025, at 11:15 a.m. ET.

A live webcast of the fireside chat will be available in the Investor section of the Company's website atwww.syndax.com, where a replay will also be available for a limited time.

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj®(revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visitwww.syndax.com/or follow the Company onXandLinkedIn.

SNDX-G